International Journal of Information Science and Computing
Citation: *IJISC*: **12**(02): 245-257, December 2025
DOI: 10.30954/2348-7437.2.2025.10

INFORMATION SCIENCE AND TECHNOLOGY FOUNDATION

REVIEW PAPER

Machine Learning Integration in Next-Generation Chemotherapy Design: Challenges, Precision Medicine and Patient-Centered Impact

Koyel Misra

NSHM Knowledge Campus, Durgapur, West Bengal, India

Corresponding author: koyel.misra@nshm.com

Received: 23 Sept., 2025 **Revised:** 24 Nov., 2025 **Accepted:** 06 Dec., 2025

ABSTRACT

Machine learning (ML) has emerged as a transformative technology in oncology, offering significant promise for advancing chemotherapy design and individualized treatment strategies. By leveraging large-scale biological, genomic, and clinical datasets, ML models can accelerate drug discovery, predict therapeutic responses, and improve toxicity management. The integration of ML enhances precision medicine approaches and supports more patient-centered cancer care. However, challenges such as data scarcity, poor model interpretability, algorithmic bias, and limited cross-disciplinary collaboration hinder its full clinical adoption. This paper explores the current applications of ML in chemotherapy development, discusses the challenges in its integration, and highlights the potential impact on precision oncology and patient quality of life.

Keywords: machine learning, chemotherapy design, precision medicine,predictive modeling, patient-centered care, oncology

Chemotherapy remains a cornerstone of cancer treatment, but its effectiveness is often limited by non-specific cytotoxicity, inter-patient variability, and treatment-related toxicities. Traditional drug development pipelines are labor-intensive, expensive, and slow, often taking more than a decade to bring a new drug to market[1].

Machine learning has emerged as a critical tool capable of transforming multiple stages of chemotherapy development—from target identification to dosing optimization. ML-driven approaches offer unprecedented capabilities in pattern recognition, predictive modeling and decision support, enabling researchers and clinicians to design safer, more effective and more personalized therapies[3].

How to cite this article: Misra, K. (2025). Machine Learning Integration in Next-Generation Chemotherapy Design: Challenges, Precision Medicine and Patient-Centered Impact. *IJISC.,* **12**(02): 245-257.

Source of Support: None; **Conflict of Interest:** None




Fig. 1: Role of machine learning in Precision medicine[2]

Table 1: Applications of Machine Learning Across the Chemotherapy Development Pipeline

Stage of Chemotherapy Design	Machine Learning Techniques	Data Types Used	Key Outcomes
Target identification	Supervised learning, deep learning	Genomic and transcriptomic data	Identification of novel cancer targets
Drug discovery and lead optimization	Graph neural networks, transformer models	Chemical structures, protein–ligand interactions	Accelerated screening of potential drug candidates
Drug–target interaction prediction	Deep learning, ensemble models	Molecular docking and bioassay data	Improved prediction of binding affinity
Treatment response prediction	Classification and regression models	Genomic, clinical, and imaging data	Personalized therapy selection
Dose optimization	Reinforcement learning	Longitudinal clinical records	Optimized efficacy with reduced toxicity

REVIEW OF LITERATURE

Role of Machine Learning in Chemotherapy Design

Machine learning plays an increasingly significant role in modern chemotherapy design by enabling faster drug discovery[4], more accurate prediction of patient responses, and improved optimization of treatment strategies. Through advanced data analysis and pattern recognition, ML helps researchers identify promising drug candidates and personalize therapy to enhance both effectiveness and patient safety[5,6].

Accelerated Drug Discovery and Lead Optimization

Machine learning is transforming the early stages of chemotherapy development by dramatically speeding up drug discovery and optimizing lead compounds. Traditional drug discovery relies heavily on trial-and-error laboratory experiments, which are time-consuming, resource-intensive, and costly. In contrast, ML models can rapidly screen millions of chemical compounds in silico[7]—that is, using computer-based simulations—before any laboratory testing begins.

These models are capable of analyzing enormous volumes of chemical and biological data to forecast how different molecules will behave in the body. They can predict the likelihood of a compound binding effectively to a specific cancer target[8,9], estimate potential toxicity to healthy cells, and identify structural features that enhance therapeutic activity. Instead of manually synthesizing and testing thousands of molecules, researchers can use ML-generated insights to focus only on the most promising candidates.

Deep learning techniques such as graph neural networks (GNNs) and transformer-based architectures have been particularly impactful in this area[10].

GNNs represent molecules as graphs, allowing the model to learn complex relationships between atoms and chemical bonds. This makes them highly effective in predicting molecular properties, drug–target interactions, and binding affinities[11,12].

Transformer models, originally developed for natural language processing, excel at identifying patterns in sequence data, making them useful for understanding protein structures, generating novel chemical compounds, and predicting reaction outcomes[13].

By guiding the selection and refinement of lead compounds, these advanced ML approaches significantly reduce the experimental workload and financial burden of early-stage drug development. They help researchers design chemotherapy agents that are more potent, more selective, and ultimately safer for patients—all while accelerating the journey from concept to clinical candidate[14].

Predicting Patient Response to Chemotherapy

Machine learning plays a crucial role in anticipating how individual patients will respond to different chemotherapeutic agents, a key step toward achieving truly personalized cancer treatment[15]. Cancer patients often show wide variability in how they react to the same drug—while some may respond well, others may experience limited effectiveness or severe toxicity[16]. ML-based predictive models help clinicians navigate this complexity by integrating and analyzing diverse biological and clinical data.

These models can identify which patients are more likely to benefit from a specific drug regimen by recognizing patterns in genomic alterations, gene expression profiles, and tumor-specific biomarkers. At the same time, ML algorithms can estimate the probability of adverse effects, enabling clinicians to proactively adjust dosages or consider alternative therapies to minimize harm. Another critical application is predicting the likelihood of drug resistance, which is a major challenge in chemotherapy[17]. By analysing tumor evolution patterns and molecular signatures, ML can alert clinicians to patients at higher risk of developing resistance, allowing timely modifications to treatment strategies.

To generate these predictions, machine learning systems draw on rich datasets, including genomic sequencing results, proteomic profiles, tumor microenvironment characteristics, imaging data, and detailed patient histories. By combining and interpreting these complex data sources, ML provides insights that would be difficult or impossible to obtain through traditional clinical methods alone.

These capabilities empower oncologists to design more precise, tailored treatment plans that maximize therapeutic benefit while reducing unnecessary toxicity. Ultimately, ML-driven predictions support better decision-making, enhance patient safety, and contribute significantly to the advancement of personalized oncology[18].

Adaptive and Dynamic Treatment Planning

Machine learning also enables chemotherapy treatment plans to become more adaptive and responsive to a patient's changing clinical condition. In real-world settings, patients undergo continuous monitoring through laboratory tests, imaging scans, electronic health records, and reports of treatment-related toxicity. This stream of data can be integrated into ML algorithms to update therapeutic decisions as a patient's status evolves[19].

By analyzing these inputs, ML systems can detect early signs of treatment effectiveness or potential complications. For example, a sudden change in blood counts, tumor size, or biomarker levels may signal that a patient needs a dose adjustment, a supportive care intervention, or even a shift to a different drug regimen. This dynamic approach reduces the reliance on fixed treatment schedules and allows care to be tailored to the individual's real-time needs[20,21].

Reinforcement learning—an advanced ML paradigm inspired by decision-making processes—is particularly promising for optimizing chemotherapy dosing strategies. These models learn from simulated or historical patient outcomes and iteratively refine dosing recommendations to achieve the best possible balance between therapeutic efficacy and toxicity. Instead of using static dosage guidelines, reinforcement learning can propose personalized dose adjustments that minimize harmful side effects while maintaining strong anti-cancer activity[22].

Overall, the integration of real-world patient data with adaptive ML models represents a major step forward in personalized oncology. It supports more flexible, precise, and patient-specific treatment planning, ultimately improving safety, treatment continuity, and clinical outcomes.

DISCUSSION & ANALYSIS

Challenges in Integrating ML into Chemotherapy Development

While machine learning offers powerful tools to advance chemotherapy design, its successful implementation is hindered by multiple challenges. Issues such as limited access to high-quality biomedical data, concerns about model interpretability, and gaps in collaboration between computational experts and clinicians continue to slow its clinical adoption.

Limited High-Quality and Standardized Data

One of the major obstacles in integrating machine learning into chemotherapy development is the scarcity of high-quality, standardized data. Although cancer research produces vast amounts of information—from genomic sequencing and imaging studies to clinical records and treatment outcomes—the data is often highly heterogeneous. Different hospitals and laboratories use varying methods for data collection, storage, and reporting, resulting in inconsistencies that make it difficult to combine datasets or train reliable ML models[24].

Additionally, much of the available data is fragmented across multiple institutions and research centers, preventing the formation of large, unified datasets required for robust model training[25]. Even when data is accessible, it is frequently insufficiently annotated, lacking detailed labels or standardized documentation that ML algorithms rely on to learn meaningful patterns.




Fig. 2: Conceptual Framework for Translational AI in Oncology[23]

Strict patient privacy regulations, while essential for protecting personal information, add another layer of complexity by limiting data sharing across institutions and countries[26]. These restrictions, though necessary, slow down the development of comprehensive datasets that could drive significant progress in ML-based chemotherapy design.

Together, these factors create a challenging environment for building accurate, generalizable models. Overcoming these data-related barriers is essential to unlocking the full potential of machine learning in oncology.

Interpretability and Clinical Trust

Oncologists require transparent reasoning behind treatment recommendations. Black-box ML models often lack interpretability, creating challenges in clinical adoption. Interpretable AI (XAI) methods must be incorporated for trust and accountability[27].

Algorithmic Bias and Lack of Generalizability

Machine learning models used in chemotherapy research and clinical decision-making often struggle when the data they are trained on does not accurately reflect the full diversity of the patient population[28].

When datasets are skewed toward certain demographic or clinical groups, the resulting algorithms tend to perform well for those groups but may under-perform for underrepresented or minority populations. This imbalance can unintentionally reinforce existing healthcare disparities, leading to unequal treatment outcomes[29].

Moreover, ensuring that these models work reliably across varied patient groups remains a major challenge. Differences in genetics, environmental factors, comorbidities, treatment responses, and healthcare access all influence how patients react to chemotherapy[30]. If these factors are not adequately captured in the training data, the model's predictions will not generalize well in real-world settings. As a result, improving dataset diversity and rigorously validating models across population subsets are essential steps toward reducing algorithmic bias and enhancing their clinical applicability[31].

Limited Cross-disciplinary Collaboration

The successful integration of machine learning into chemotherapy development depends on strong collaboration among multiple expert groups, including data scientists, oncologists, pharmacologists, and bioinformaticians[32]. Each of these professionals brings a unique perspective—ranging from computational modeling and clinical insight to drug mechanisms and biological data interpretation. When these viewpoints are effectively combined, machine learning systems can be designed and refined in ways that truly support clinical decision-making and therapeutic innovation[33].

However, in practice, gaps in communication and differences in domain knowledge often slow progress. Technical concepts may not translate easily across disciplines, leading to misunderstandings about model capabilities, data requirements, or clinical relevance. Similarly, clinicians may have practical insights that are difficult to quantify, while data specialists may focus heavily on algorithmic performance without fully grasping real-world constraints. Overcoming these communication barriers is essential to building robust, clinically meaningful ML tools that can advance chemotherapy research and patient care.

FINDINGS

Machine learning is rapidly transforming the way clinicians understand cancer biology and tailor treatments to individual patients. By analyzing vast amounts of genomic, clinical, and molecular data, ML models can uncover subtle patterns that guide more accurate diagnosis, predict treatment response, and identify personalized therapeutic strategies. This data-driven approach moves beyond traditional one-size-fits-all methods, paving the way for truly individualized cancer care and more effective chemotherapy planning[34].

Genomic-Guided Chemotherapy

Machine learning plays a pivotal role in advancing precision oncology by integrating complex multi-omics datasets—such as genomics, transcriptomics, proteomics, and metabolomics—into cohesive, interpretable insights. By bringing together these diverse layers of biological information, ML models can identify meaningful biomarkers that guide clinical decisions, reveal how specific genomic alterations influence drug sensitivity, and support the selection of therapies tailored to the unique molecular characteristics of a patient's tumor[35].

This integrative capability moves cancer care closer to true personalization. Instead of relying solely on generalized treatment protocols, clinicians can use ML-driven analyses to design individualized therapeutic strategies that maximize efficacy while reducing unnecessary toxicity[36]. In this way, machine learning

acts as a powerful enabler of precision medicine, helping translate molecular data into targeted, patient-specific chemotherapy plans.

Table 2: Role of Machine Learning in Enabling Precision Medicine

Precision Medicine Aspect	ML Contribution	Clinical Benefit
Genomic-guided chemotherapy	Identification of predictive biomarkers	Improved treatment matching
Toxicity prediction	Risk stratification models	Reduction of adverse effects
Drug resistance prediction	Detection of tumor evolution patterns	Early therapeutic adjustments
Combination therapy design	Prediction of synergistic drug interactions	Enhanced treatment efficacy
Adaptive treatment planning	Continuous learning from patient data	Personalized dose optimization

Predicting and Managing Toxicity

Machine learning has emerged as a valuable tool for forecasting chemotherapy-related toxicities, which are often unpredictable and vary widely across patients[37]. By analyzing clinical histories, laboratory parameters, treatment regimens, and genetic markers, ML-based side-effect prediction models can anticipate complications such as neutropenia, organ-specific toxicity, and other severe adverse events[38]. These insights help clinicians better understand which patients are at higher risk and why certain reactions may occur.

Early identification of potential toxicities enables a more proactive and personalized approach to patient care. Clinicians can adjust chemotherapy doses before complications arise, implement targeted supportive care strategies, and closely monitor vulnerable patients. This not only reduces preventable treatment interruptions but also enhances overall patient safety and quality of life. Ultimately, ML-driven toxicity prediction supports more precise, responsive, and safer chemotherapy management.

Personalized Drug Combination Design

Machine learning is increasingly being used to refine and optimize combination therapies in oncology, where selecting the right drug pairs can significantly improve treatment outcomes. By analyzing large datasets on drug mechanisms, molecular pathways, and patient responses, ML models can predict which combinations are likely to produce synergistic effects—where two drugs work more effectively together than individually. These models also help identify and avoid pairs that may lead to overlapping toxicities, ensuring patient safety remains a priority[39].

Beyond safety considerations, ML-driven insights allow researchers and clinicians to design therapeutic strategies that simultaneously target multiple signaling pathways involved in cancer progression. This multi-targeted approach can enhance treatment efficacy, overcome resistance mechanisms, and provide more durable clinical responses[40]. Ultimately, the use of machine learning in combination therapy development supports more rational, efficient, and patient-centered treatment planning.

RECOMMENDATIONS

The integration of machine learning into chemotherapy development is not only a technological

advancement but also a significant step toward improving the overall patient experience[41]. By enabling more accurate predictions, personalized treatment plans, and proactive toxicity management, ML enhances both the safety and effectiveness of cancer care. These innovations ultimately place the patient at the center of decision-making, ensuring that treatments are better aligned with individual needs and well-being.

Improved Treatment Outcomes

Machine learning significantly enhances treatment outcomes by enabling chemotherapy plans that are closely aligned with each patient's unique clinical and biological profile. Instead of relying on generalized dosing or standard protocols, ML-driven models analyze patterns in genetics, biomarkers, medical history, and prior treatment responses to recommend therapies that are most likely to be effective for a specific individual.

This personalized approach can substantially increase the therapeutic impact of chemotherapy, ensuring that the chosen drugs and dosages are optimally suited to the patient's tumor characteristics. At the same time, by predicting potential side effects and identifying patients at higher risk of complications, ML helps reduce adverse events and prevent avoidable toxicity. Fewer complications translate into fewer interruptions, meaning patients are more likely to complete their treatment as planned[42].

Overall, ML-guided chemotherapy supports safer, more effective cancer care—improving both short-term treatment success and long-term patient outcomes.

Enhanced Quality of Life

Machine learning–enabled personalization of toxicity management plays a crucial role in improving the overall quality of life for patients undergoing chemotherapy. By predicting which individuals are likely to experience specific side effects, clinicians can intervene early with tailored dose adjustments, preventive medications, or closer monitoring. This proactive approach helps reduce the likelihood of severe toxicities that often lead to emergency visits or prolonged hospital stays, thereby lowering hospitalization rates[43].

Better anticipation and management of symptoms also mean that patients experience a lower physical and emotional burden throughout their treatment journey. When side effects are minimized or controlled effectively, individuals can maintain greater comfort, energy, and daily functioning[44]. As a result, patients are better able to carry out normal activities, preserve independence, and sustain a more positive outlook during therapy.

In essence, personalized toxicity management not only supports safer treatment but also contributes significantly to better functional outcomes and a more manageable treatment experience.

Empowerment Through Predictive Insights

Machine learning–powered decision support tools give patients access to clearer, more personalized information about their treatment journey. By analyzing individual clinical and molecular data, these tools can provide realistic expectations about how a patient might respond to specific chemotherapy regimens. They also help outline the potential risks and benefits of each option, offering a more transparent view of possible outcomes and side effects. In doing so, these systems support shared decision-making by enabling

patients and clinicians to engage in more informed and meaningful discussions about treatment choices. ML-driven insights can also adapt as new patient data become available, allowing recommendations to evolve over time in response to treatment progress or emerging complications. This dynamic feedback enhances patient confidence, reduces uncertainty, and promotes a greater sense of involvement and autonomy in the decision-making process.

With this deeper understanding, patients become more active participants in their care. They can explore alternative therapy choices, weigh them against predicted outcomes, and discuss these insights with their healthcare team. This fosters a more collaborative approach to treatment planning, where decisions are made jointly rather than solely directed by clinicians. In turn, patients gain a stronger sense of control and autonomy, feeling more informed, confident, and engaged in shaping their own treatment paths[45,46].

FUTURE DIRECTIONS

Advancing machine learning in chemotherapy design will require sustained focus on several critical priorities[47]. First, the creation of large, diverse, and standardized oncology datasets is essential. Robust datasets that represent varied patient populations enable ML models to generate more accurate, generalizable, and equitable predictions. Standardization across institutions also improves data quality, making it easier to share, integrate, and analyze information at scale.

Equally important is the development of interpretable and ethically responsible ML models. Clinicians must be able to understand how a model arrives at its recommendations to ensure transparency, trust, and safe application in high-stakes clinical settings[48,49]. Ethical considerations—including fairness, accountability, and bias mitigation—will remain central to responsible implementation.

Integrating ML tools into electronic health records and routine clinical workflows is another key priority. Embedding predictive insights directly into the systems clinicians use every day will streamline decision-making and ensure that AI guidance is both accessible and actionable. Achieving this will demand stronger interdisciplinary collaboration among oncologists, data scientists, pharmacologists, and regulatory experts, ensuring that tools are clinically meaningful and technologically sound[50].

Regulatory agencies will also play an increasingly important role by providing clearer guidelines for evaluating, approving, and monitoring AI-driven therapies. Such frameworks will help maintain safety, reliability, and public confidence as these tools become more widely adopted[51].

Looking ahead, the future of chemotherapy design is likely to embrace hybrid systems that combine mechanistic modeling, high-throughput biological experimentation, and AI-based predictive analytics[52]. This integrated approach will enable highly precise, patient-specific treatment strategies—bringing the vision of truly personalized cancer therapy closer to reality.

CONCLUSION

Machine learning (ML) is transforming the future of chemotherapy by fundamentally reshaping how anticancer drugs are discovered, how therapeutic decisions are formulated, and how treatment is customized for individual patients. By leveraging its capacity to process and analyze massive, multidimensional datasets—including genomic, proteomic, metabolomic, imaging, and clinical data—ML enables researchers to identify promising drug candidates with unprecedented speed and precision. Advanced algorithms can recognize subtle biological patterns and complex molecular interactions that often remain

undetected through conventional analytical approaches, thereby accelerating target identification and lead optimization in drug development. This data-driven paradigm significantly reduces both the time and cost associated with bringing new chemotherapeutic agents from the laboratory to clinical trials.

Beyond drug discovery, ML plays an increasingly critical role in precision oncology by guiding treatment selection and optimization. Cancer is a highly heterogeneous disease, and patients with similar clinical diagnoses often exhibit markedly different responses to the same chemotherapeutic regimen. ML models can integrate patient-specific molecular profiles with historical treatment outcomes to predict drug sensitivity, resistance mechanisms, and optimal dosing strategies. This enables clinicians to move away from a "one-size-fits-all" approach toward therapies that are precisely aligned with the genetic and biological characteristics of an individual tumor. Such personalization not only enhances therapeutic efficacy but also minimizes unnecessary exposure to toxic agents.

In clinical settings, ML-driven tools are increasingly used to monitor treatment response, predict adverse effects, and support real-time decision-making. By continuously analyzing longitudinal patient data—such as laboratory parameters, imaging findings, and reported symptoms—ML systems can detect early signs of toxicity or treatment failure. This allows clinicians to proactively adjust chemotherapy regimens, improve supportive care, and reduce the likelihood of severe complications. Furthermore, predictive models can estimate patient prognosis and survival outcomes, aiding in informed clinical discussions and shared decision-making between physicians and patients. Despite these transformative capabilities, several challenges must be addressed to fully harness the potential of ML in chemotherapy. High-quality, well-annotated, and diverse datasets are essential for building robust and generalizable models, yet data fragmentation, privacy concerns, and institutional silos continue to limit data availability. Model interpretability also remains a major concern, as black-box algorithms may hinder clinical trust and adoption. Developing explainable AI frameworks that provide transparent and clinically meaningful insights is therefore a critical priority. Equally important is fostering interdisciplinary collaboration among oncologists, data scientists, pharmacologists, and bioinformaticians to ensure that ML solutions are both technically sound and clinically relevant.

As ML technologies continue to advance and integrate more deeply into research pipelines and healthcare infrastructures, their impact on chemotherapy is expected to expand further. These innovations hold the promise of safer, more effective, and highly individualized treatment strategies that adapt dynamically to patient responses. In the long term, the convergence of ML and oncology is poised to improve treatment success rates, enhance quality of life, and contribute to improved survival outcomes for cancer patients worldwide, marking a significant step toward truly intelligent, data-driven cancer care.

REFERENCES

1. Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., … Dean, J. 2019. A guide to deep learning in healthcare. *Nature Medicine,* **25**(1): 24–29.

2. Topol, E.J. 2019. High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine,* **25**(1): 44–56.

3. Kourou, K., Exarchos, T.P., Exarchos, K.P., Karamouzis, M.V. and Fotiadis, D.I. 2015. Machine learning applications in cancer prognosis and prediction. *Computational and Structural Biotechnology Journal,* **13**: 8–17.

4. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., … Wierling, C. 2019. Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery,* **18**(6): 463–477.

5. Zhavoronkov, A., Ivanenkov, Y.A., Aliper, A., Veselov, M.S., Aladinskiy, V.A., Aladinskaya, A.V., … Aspuru-Guzik, A. 2019. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nature Biotechnology,* **37**(9): 1038–1040.

6. Gawehn, E., Hiss, J.A. and Schneider, G. 2016. Deep learning in drug discovery. *Molecular Informatics,* **35**(1): 3–14.

7. Chen, R. and Snyder, M. 2013. Promise of personalized omics to precision medicine. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine,* **5**(1): 73–82.

8. Kourou, K., Fotiadis, D.I. and Exarchos, T.P. 2014. Predictive modeling in oncology using machine learning. *Bioinformatics,* **30**(24): 3451–3458.

9. Ching, T., Himmelstein, D.S., Beaulieu-Jones, B.K., Kalinin, A.A., Do, B.T., Way, G.P., … Greene, C.S. 2018. Opportunities and obstacles for deep learning in biology and medicine. *Journal of The Royal Society Interface,* **15**(141): 20170387.

10. Libbrecht, M.W. and Noble, W.S. 2015. Machine learning applications in genetics and genomics. *Nature Reviews Genetics,* **16**(6): 321–332.

11. Wainberg, M., Merico, D., Delong, A. and Frey, B.J. 2018. Deep learning in biomedicine. *Nature Biotechnology,* **36**(9): 829–838.

12. Armitage, J.O. 2017. Early-stage Hodgkin's lymphoma. *New England Journal of Medicine,* **377**(23): 2294–2305.

13. Ho, D., Quake, S.R., McCabe, E.R.B., Chng, W.J., Chow, E.K.H., Ding, X., … Snyder, M. 2020. Enabling technologies for personalized and precision medicine. *Trends in Biotechnology,* **38**(5): 497–518.

14. LeCun, Y., Bengio, Y. and Hinton, G. 2015. Deep learning. *Nature,* **521**(7553): 436–444.

15. Beam, A.L. and Kohane, I.S. 2018. Big data and machine learning in health care. *JAMA,* **319**(13): 1317–1318.

16. Rajkomar, A., Dean, J. and Kohane, I. 2019. Machine learning in medicine. *New England Journal of Medicine,* **380**(14): 1347–1358.

17. Ghassemi, M., Oakden-Rayner, L. and Beam, A. 2021. The false hope of current approaches to explainable AI in health care. *The Lancet Digital Health,* **3**(11): e745–e750.

18. Ribeiro, M.T., Singh, S. and Guestrin, C. 2016. "Why should I trust you?" Explaining predictions of any classifier. *Proceedings of the ACM SIGKDD*, pp. 1135–1144. https://doi.org/10.1145/2939672.2939778

19. Samek, W., Wiegand, T. and Müller, K.R. 2017. Explainable artificial intelligence. *IEEE Signal Processing Magazine,* **34**(4): 107–110.

20. Obermeyer, Z., Powers, B., Vogeli, C. and Mullainathan, S. 2019. Dissecting racial bias in an algorithm used to manage population health. *Science,* **366**(6464): 447–453.

21. Chen, I.Y., Johansson, F.D. and Sontag, D. 2018. Why is my classifier discriminatory? *Advances in Neural Information Processing Systems*, pp. 3539–3550.

22. Mak, K.K. and Pichika, M.R. 2019. Artificial intelligence in drug development. *Drug Discovery Today,* **24**(3): 773–780.

23. Wishart, D.S. 2016. Improving early drug discovery through ADMET modeling. *Drug Discovery Today,* **21**(5): 735–742.

24. Al-Lazikani, B., Banerji, U. and Workman, P. 2012. Combinatorial drug therapy for cancer. *Nature Biotechnology,* **30**(7): 679–692.

25. Iorio, F., Knijnenburg, T.A., Vis, D.J., Bignell, G.R., Menden, M.P., Schubert, M., … Saez-Rodriguez, J. 2016. A landscape of pharmacogenomic interactions in cancer. *Cell,* **166**(3): 740–754.

26. Zhang, L. and Yu, J. 2020. Role of AI in precision oncology. *Precision Clinical Medicine,* **3**(3): 164–173.

27. Raghupathi, W. and Raghupathi, V. 2014. Big data analytics in healthcare. *Health Information Science and Systems,* **2**(1): 3.

28. Bibault, J.E., Giraud, P. and Burgun, A. 2016. Big data and machine learning in radiation oncology. *The Lancet Oncology,* **17**(7): e284–e295.

29. Kelly, C.J., Karthikesalingam, A., Suleyman, M., Corrado, G. and King, D. 2019. Key challenges for delivering clinical impact with artificial intelligence. *BMC Medicine,* **17**: 195.

30. Price, W.N. and Cohen, I.G. 2019. Privacy in the age of medical big data. *Nature Medicine,* **25**(1): 37–43.

31. Kalia, M. (2015). Personalized oncology. *The EPMA Journal, 6*, 12. https://doi.org/10.1186/s13167-015-0039-6

32. Yu, K.H., Beam, A.L. and Kohane, I.S. 2018. Artificial intelligence in healthcare. *Nature Biomedical Engineering,* **2**(10): 719–731.

33. Gillies, R.J., Kinahan, P.E. and Hricak, H. 2016. Radiomics. *Radiology,* **278**(2): 563–577.

34. Lambin, P., Rios-Velazquez, E., Leijenaar, R., Carvalho, S., van Stiphout, R.G., Granton, P. … Dekker, A. 2012. Radiomics. *European Journal of Cancer,* **48**(4): 441–446.

35. Holzinger, A., Biemann, C., Pattichis, C.S. and Kell, D.B. 2017. What do we need to build explainable AI systems? *arXiv preprint arXiv:1712.09923*.

36. Sanchez, M.M. and Aerts, H.J.W.L. 2020. Artificial intelligence in radiotherapy. *Nature Reviews Clinical Oncology,* **17**(4): 209–210.

37. Fogel, D.B. 2018. Factors associated with clinical trials that fail. *Contemporary Clinical Trials Communications,* **11**: 156–164.

38. Collins, F.S. and Varmus, H. 2015. A new initiative on precision medicine. *New England Journal of Medicine,* **372**(9): 793–795.

39. Johnson, K.W., Torres Soto, J., Glicksberg, B.S., Shameer, K., Miotto, R., Ali, M., … Dudley, J.T. 2018. Artificial intelligence in cardiology. *Journal of the American College of Cardiology,* **71**(23): 2668–2679.

40. Sidey-Gibbons, J.A.M. and Sidey-Gibbons, C.J. 2019. Machine learning in medicine. *BMC Medical Research Methodology,* **19**: 64.

41. Shortliffe, E.H. and Sepúlveda, M.J. 2018. Clinical decision support in the era of AI. *JAMA,* **320**(21): 2199–2200.

42. He, K.Y., Ge, D. and He, M.M. 2019. Big data analytics for genomic medicine. *International Journal of Molecular Sciences,* **20**(2): 292.

43. Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., … Giaccone, G. 2015. Molecular profiling and targeted therapy. *Journal of Clinical Oncology,* **33**(6): 611–619.

44. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M. and Blaschke, T. 2018. The rise of deep learning in drug discovery. *Drug Discovery Today,* **23**(6): 1241–1250.

45. Mak, K.K. and Pichika, M.R. 2019. Artificial intelligence in drug development. *Drug Discovery Today,* **24**(3): 773–780.

46. Mathur, P. and Sutton, J. 2017. Personalized medicine. *British Journal of Clinical Pharmacology,* **83**(1): 7–13.

47. Shah, P., Kendall, F., Khozin, S., Goosen, R., Hu, J., Laramie, J., … Schork, N. 2019. Artificial intelligence and machine learning in clinical development. *NPJ Digital Medicine,* **2**: 69.

48. Beam, A.L. and Kohane, I.S. 2017. Translating AI into clinical care. *JAMA,* **316**(22): 2357–2358.

49. Lovejoy, C.A. and Tainsky, M.A. 2019. Genomics-driven oncology. *Cancer Discovery,* **9**(10): 1354–1361.

50. Friedman, C.P., Wong, A.K. and Blumenthal, D. 2010. Achieving a nationwide learning health system. *Science Translational Medicine,* **2**(57): 57cm29.

51. Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S. and Vale, N. 2024. Advancing precision medicine: A review of innovative *in silico* approaches for drug development, clinical pharmacology and personalized healthcare. *Pharmaceutics,* **16**(3): 332.

52. Zhang, L., Wang, Y., Li, H., Chen, Z. and Liu, Q. 2025. Artificial intelligence–driven precision oncology: Opportunities, challenges, and future perspectives. *Molecular Cancer,* **24**: Article 369.